Recombinant Human MSLN (Myc Tag, His Tag)
ED50
/
Species
Human
Purity
>90 %, SDS-PAGE
GeneID
10232
Accession
Q13421
验证数据展示
Technical Specifications
Purity | >90 %, SDS-PAGE |
Endotoxin Level | <1.0 EU/μg protein, LAL method |
Biological Activity |
/ |
Source | HEK293-derived Human MSLN protein Glu296-Ser606 (Accession# Q13421) with a Myc Tag and a His Tag at the C-terminus. |
Predicted Molecular Mass | 37.1 kDa |
SDS-PAGE | 40-70 kDa, reducing (R) conditions |
Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Mesothelin (MSLN) is a glycosylphosphatidylinositol-linked membrane glycoprotein which is highly expressed in a variety of tumors and is also expressed in mesothelial cells of healthy individuals, but at low levels. Therefore, it can be considered as a promising target protein for tumor-targeted therapy. In the tumor environment, MSLN plays an important role in survival, proliferation, and migration/invasion of cancer cells as well as in drug resistance.
References:
1. Zeng W, Pan J, Fang Z, Jia J, Zhang R, He M, Zhong H, He J, Yang X, Shi Y, Zhong B, Zeng J, Fu B, Huang M, Liu H. A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy. Front Immunol. 2022 Jun 20;13:925217. 2. Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, et al.. Mesothelin-Specific CAR T Cells Target Ovarian Cancer. Cancer Res (2021) 81:3022–35. 3. Weidemann S, Gagelmann P, Gorbokon N, Lennartz M, Menz A, Luebke AM, et al.. Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines (2021) 9:397. 4. Le K, Wang J, Zhang T, Guo Y, Chang H, Wang S, et al.. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC). Int J Med Sci (2020) 17:422–7. 5. Del Bano J, Florès-Florès R, Josselin E, Goubard A, Ganier L, Castellano R, et al.. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer. Front Immunol (2019) 10:1593.